Annals of Clinical Microbiology and Antimicrobials | |
Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales | |
Research | |
M. Ávila-Núñez1  P. Rubiñán1  M Rubianes1  M. Represa1  L. García-Formoso1  P. Celestino1  M. Garrido-Ventín1  O. Lima2  A. Sousa2  MT. Pérez-Rodríguez2  L. Martinez-Lamas3  F. Vasallo-Vidal3  A. Pérez-Landeiro4  | |
[1] Infectious Diseases Unit. Internal Medicine Department, Complexo Hospitalario Universitario de Vigo, Galicia, Spain;Infectious Diseases Unit. Internal Medicine Department, Complexo Hospitalario Universitario de Vigo, Galicia, Spain;Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain;Microbiology Department, Complexo Hospitalario Universitario de Vigo, Galicia, Spain;Pharmacy Department, Complexo Hospitalario Universitario de Vigo, Galicia, Spain; | |
关键词: Bacteremia; Enterobacterales; AmpC-producing; Carbapenem; Cefepime; Piperacillin-tazobactam; | |
DOI : 10.1186/s12941-023-00624-9 | |
received in 2023-03-13, accepted in 2023-07-29, 发布年份 2023 | |
来源: Springer | |
【 摘 要 】
IntroductionCarbapenems (CR) have traditionally been the first line treatment for bacteremia caused by AmpC-producing Enterobacterales. However, CR have a high ecological impact, and carbapenem-resistant strains continue rising. Thus, other treatment alternatives like Piperacillin-Tazobactam (P-T) or Cefepime (CEF) and oral sequential therapy (OST) are being evaluated.MethodsWe conducted a retrospective, single-centre observational study. All adult patients with AmpC-producing Enterobacterales bacteremia were included. The primary endpoint was clinical success defined as a composite of clinical cure, 14-day survival, and no adverse events. We evaluated the evolution of patients in whom OST was performed.ResultsSeventy-seven patients were included, 22 patients in the CR group and 55 in the P-T/CEF group (37 patients received CEF and 18 P-T). The mean age of the patients was higher in the P-T/CEF group (71 years in CR group vs. 76 years in P-T/CEF group, p = 0.053). In the multivariate analysis, age ≥ 70 years (OR 0.08, 95% CI [0.007–0.966], p = 0.047) and a Charlson index ≥ 3 (OR 0.16, 95% CI [0.026–0.984], p = 0.048), were associated with a lower clinical success. Treatment with P-T/CEF was associated with higher clinical success (OR 7.75, 95% CI [1.273–47.223], p = 0.026). OST was performed in 47% of patients. This was related with a shorter in-hospital stay (OST 14 days [7–22] vs. non-OST 18 days [13–38], p = 0.005) without difference in recurrence (OST 3% vs. non-OST 5%, p = 0.999).ConclusionsTargeted treatment with P-T/CEF and OST could be safe and effective treatments for patients with AmpC-producing Enterobacterales bacteremia.
【 授权许可】
CC BY
© BioMed Central Ltd., part of Springer Nature 2023
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202309153808369ZK.pdf | 1009KB | download | |
Fig. 2 | 2478KB | Image | download |
Fig. 6 | 77KB | Image | download |
【 图 表 】
Fig. 6
Fig. 2
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]